Clinical Trial Update: Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of a personalized tumor neoantigen mRNA therapy for advanced pancreatic cancer; study status currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Personalized tumor neoantigen mRNA therapy

Snippet

Sponsor: Zhejiang University | Conditions: Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING